Christophe Boetsch
0009-0005-8467-0339
Roche (Switzerland)
2 papers found
Refreshing results…
Phase II study to determine the anti-tumor activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in esophageal cancer
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Missing publications? Search for publications with a matching author name.